

Syngene

Ref: Syn/Acts/CS/SE/PR/BSE/NSE

Syngene International Limited

Biocon Park SEZ, Bommasandra IV Phase
Jigani Link Road, Bangalore 560099, India
T +91 80 6775 5000
F +91 80 4014 3150/2850 3423
CIN: L85110KA1993PLC014937

www.syngeneintl.com

September 21, 2016

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
---	---

Dear Sir/Madam,

Subject: Press Release

This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **“Syngene International closes deal with Strand Life Sciences to Purchase Systems Biology and Pharma Services Practice”**.

The above mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Mayank Verma

Mayank Verma

Company Secretary

E: Mayank.verma@syngeneintl.com

M: +91 97399 04949

T: + 91 80 6775 8781



PRESS RELEASE

Syngene International closes deal with Strand Life Sciences to Purchase Systems Biology and Pharma Services Practice

Deal boosts Syngene's Bioinformatics and Data Analytics capabilities

Bangalore, India: 21st September, 2016: Syngene International Ltd., Asia's leading Contract Research Organization, and Strand Life Sciences, today announced that they have completed a deal through which Syngene has purchased assets of Strand Life Sciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team. Financial details of the deal were not disclosed.

Commenting on this development, **Jonathan Hunt, Chief Executive Officer, Syngene International** said, *"Given the vast volumes of genetic material sequence data that is being generated globally, there is an increasing focus on biological information management and data analytics in drug discovery and development. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities. We believe Strand's bioinformatics platforms not only complement our existing integrated service platforms but will also meet our customers growing needs for bioinformatics and data analytic support."*

Chairman and Managing Director of Strand Life Sciences, Dr. Vijay Chandru, added *"Strand is glad that the deal with Syngene gives it access to technologies from Strand to form part of its integrated discovery service offerings. This transaction is also*

a key step for Strand to focus its energies on personalized medicine through clinical applications of all its genomics technologies.”

Bioinformatics is a rapidly emerging area that promises tremendous growth potential. Companies involved in pharmaceutical, cosmetics, FMCG and agro-biotech R&D have strong focus on genomics, and need sound bioinformatics applications and platforms for developing better therapeutics and products. According to Transparency Market Research, the global bioinformatics market was estimated at \$2.3 billion in 2012 and is forecasted to reach a market size of \$9.1 billion in 2018, at a CAGR of 25.4%.

This deal gives Syngene access to Strand’s patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratory-based experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data.

About Syngene International Limited

Syngene International Limited, (BSE code: 539268, NSE Symbol: SYNGENE, ISIN Id: INE398R01022) is one of Asia’s largest Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. Syngene offers an integrated platform for R&D focussed organizations to optimize their R&D investments and develop their novel molecules with a distinctive cost advantage. In FY2016, Syngene serviced 256 clients including 8 of the top 10 global pharma companies. For more details, visit: www.syngeneintl.com

About Strand Life Science Private Limited

Strand Life Sciences is a global genomic profiling company and leader in precision medicine diagnostics, aimed at empowering cancer care and genetic testing for inherited diseases. Strand works with physicians and hospitals to enable faster clinical decision support for accurate molecular diagnosis, prognosis, therapy recommendations, and clinical trials. The

Strand Center for Genomics & Personalized Medicine is India's 1st and only CAP & NABL accredited NGS laboratory. For more details, visit: www.strandls.com

Investor Contact	Media Contact
Syngene International Ltd.	
Dinesh Iyer ☎: +91 80 2808 3912 📞: +91 99866 91350 Fax: +91 80 2852 3423 ✉: dinesh.iyer@syngeneintl.com	Sandeep Nair ☎: +91 80 6775 8775 📞: +91 88843 67776 Fax: +91 80 2852 3423 ✉: sandeep.nair@syngeneintl.com
Strand Life Sciences	
	Ogilvy PR, Bangalore Soumita Majumdar, +91-98865-31605 soumita.majumdar@ogilvy.com or Akriti Agrawal, +91-95359-33426 akriti.agrawal@ogilvy.com